drugset / Trial / NCT05787288

A Clinical Study on Safety and Effectiveness of Mesenchymal Stem Cell Exosomes for the Treatment of COVID-19.

NCT05787288 ↗

RandomizedParallel-groupSingle-blindTreatment

Summary

This clinical study aims to investigate the safety and efficacy of nebulized inhalation of extracellular vesicles derived from mesenchymal stem cells combined with standard therapy for COVID-19-infected individuals. The primary objective is to determine whether nebulized MSC-secreted extracellular vesicles may be a feasible approach to alleviate COVID-19-induced lung injuries and promote recovery. Participants will be allocated to receive either nebulized MSC-secreted extracellular vesicles twice a day (BID) for 5 days as the test group or nebulized saline solution twice a day for 5 days as the control group. Researchers will compare the test and control groups to evaluate the safety and efficacy of extracellular vesicles in combination with standard therapy.

Timeline

Start
2023-01-23
Primary completion
2024-01-23
Completion
2025-01-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Extracellular Vesicles from Mesenchymal Stem Cells Other / unclassified 5 ml Inhaled

Indications